...
首页> 外文期刊>Cell death & disease. >Interaction of calcium binding protein S100A16 with myosin-9 promotes cytoskeleton reorganization in renal tubulointerstitial fibrosis
【24h】

Interaction of calcium binding protein S100A16 with myosin-9 promotes cytoskeleton reorganization in renal tubulointerstitial fibrosis

机译:钙结合蛋白S100A16与肌球蛋白-9的相互作用促进肾小管间纤维化纤维化中的细胞骨架重组

获取原文
           

摘要

Renal fibrosis arises by the generation of matrix-producing fibroblasts and myofibroblasts through the epithelial–mesenchymal transition (EMT), a process in which epithelial cells undergo a transition into a fibroblast phenotype. A key feature of the EMT is the reorganization of the cytoskeletons, which may involve the Ca2+-binding protein S100A16, a newly reported member of the S100 protein family. However, very few studies have examined the role of S100A16 in renal tubulointerstitial fibrosis. In this study, S100A16 expression was examined by immunohistochemical staining of kidney biopsy specimens from patients with various nephropathies and kidney tissues from a unilateral ureteral obstruction (UUO) mouse model. Renal histological changes were investigated in S100A16Tg, S100A16+/?, and WT mouse kidneys after UUO. The expression of epithelia marker E-cadherin, mesenchymal markers N-cadherin, and vimentin, extracellular matrix protein, and S100A16, as well as the organization of F-actin, were investigated in S100A16 overexpression or knockdown HK-2 cells. Mass spectrometry was employed to screen for S100A16 binding proteins in HK-2 cells. The results indicated that S100A16 is high expressed and associated with renal tubulointerstitial fibrosis in patient kidney biopsies and in those from UUO mice. S100A16 promotes renal interstitial fibrosis in UUO mice. S100A16 expression responded to increasing Ca2+ and interacted with myosin-9 during kidney injury or TGF-β stimulation to promote cytoskeleton reorganization and EMT progression in renal tubulointerstitial fibrosis. Therefore, S100A16 is a critical regulator of renal tubulointerstitial fibroblast activation and is therefore a potential therapeutic target for the treatment of renal fibrosis.
机译:通过上皮 - 间充质转变(EMT)产生基质生成的成纤维细胞和肌纤维细胞的产生基质的成纤维细胞和髓细胞的肾纤维化,该方法是上皮细胞经历过渡到成纤维细胞表型的过程。 EMT的关键特征是细胞骨骼的重组,其可涉及Ca2 + - 粘合蛋白S100a16,该蛋白质S100A16是S100蛋白家族的新报告的成员。然而,很少有研究检测了S100A16在肾小管注入纤维化中的作用。在本研究中,通过来自单侧输尿管阻塞(UUO)小鼠模型的各种肾病和肾组织患者的肾活检标本的免疫组织化学染色来检查S100A16表达。在UUO之后,在S100A16Tg,S100A16 + /α,S100A16 + /α,S100A16 + /α.和WT小鼠肾脏中研究了肾组织学变化。在S100A16过表达或敲低HK-2细胞中研究了上皮内标记型蛋白酶,间充质标记物N-钙粘蛋白,间充质标记物N-钙粘蛋白,细胞外基质基质蛋白和S100A16的组织,以及F-Actin的组织。使用质谱法在HK-2细胞中筛选S100A16结合蛋白。结果表明,S100A16高表达和与患者肾脏活检中的肾小管间纤维化和来自Uuo小鼠的纤维化。 S100A16促进UUO小鼠中的肾间质纤维化。 S100A16表达响应于增加Ca2 +,并在肾损伤期间与肌球蛋白-9相互作用,或TGF-β刺激,以促进细胞骨架重组和EMT进展在肾小管间纤维化中。因此,S100A16是肾小管间成纤维细胞活化的临界调节剂,因此是治疗肾纤维化的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号